Pacira BioSciences Appoints Donald C. Manning, M.D., Ph.D. as Chief Medical Officer

-- Veteran Industry Executive and Anesthesiologist Brings Significant Clinical and Commercial Experience in Pain Management --

PARSIPPANY, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announces the appointment of Donald C. Manning, M.D., Ph.D., as the Company’s Chief Medical Officer, effective immediately. Dr. Manning, who brings more than 20 years of experience in biopharmaceutical executive leadership, was most recently, Chief Medical Officer at Adynxx, Inc., a development company focused on advancing disease-modifying products for the treatment of pain management and inflammation. In his new position, Dr. Manning will report directly to David Stack, chairman and chief executive officer of Pacira BioSciences. 

“We are delighted to have Don join our leadership team. Don’s deep domain expertise in both anesthesiology and pharmacology will be of great value as we advance the commercial and clinical development of our non-opioid pain management portfolio. His career-long focus on patient quality of care is an excellent fit with our vision and culture, which is dedicated to making a fundamental difference in patients’ lives,” said Mr. Stack.

“I am excited to be joining a talented and dedicated leadership team and to be working on the cutting edge of innovative technologies to provide opioid-sparing pain management to patients across a variety of surgical and rehabilitative settings. I look forward to applying my experiences in the commercial and clinical development of novel pain management solutions to help solve the devastating medical complications associated with opioid misuse and abuse,” commented Dr. Manning.
                                                            
Since 2012, Dr. Manning has served as Chief Medical Officer of Adynxx, Inc.,  Prior to Adynxx, Dr. Manning had a 14-year career in the pharmaceutical industry where he held positions of increasing scope and responsibility starting at Novartis, where he served as Global Head of Analgesics Development to Celgene, where he was Vice President and Neurosciences Therapeutic Area Head. Subsequent to that, Dr. Manning served as Vice President and Head of Clinical Development at Alpharma, as Vice President of Medical Affairs at King Pharma, and as Executive Vice President and Chief Medical Officer at Shionogi Inc.